Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

NCT00657904 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3618

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-metastatic Prostate Cancer

Interventions

DRUG: Bicalutamide
DRUG: Placebo

Sponsor

AstraZeneca